Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction
Authors
Keywords
-
Journal
mAbs
Volume 6, Issue 6, Pages 1560-1570
Publisher
Informa UK Limited
Online
2014-10-31
DOI
10.4161/19420862.2014.975099
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+T cells
- (2014) Debbie C Strachan et al. OncoImmunology
- Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors
- (2013) Sunil Sharma et al. INVESTIGATIONAL NEW DRUGS
- APG350 Induces Superior Clustering of TRAIL Receptors and Shows Therapeutic Antitumor Efficacy Independent of Cross-Linking via Fc Receptors
- (2013) C. Gieffers et al. MOLECULAR CANCER THERAPEUTICS
- Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects
- (2013) J. E. Allen et al. Science Translational Medicine
- Proapoptotic Activation of Death Receptor 5 on Tumor Endothelial Cells Disrupts the Vasculature and Reduces Tumor Growth
- (2012) Nicholas S. Wilson et al. CANCER CELL
- Nanobodies Targeting the Hepatocyte Growth Factor: Potential New Drugs for Molecular Cancer Therapy
- (2012) M. J. W. D. Vosjan et al. MOLECULAR CANCER THERAPEUTICS
- Small-molecule activation of the TRAIL receptor DR5 in human cancer cells
- (2012) Gelin Wang et al. Nature Chemical Biology
- Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fc receptor engagement
- (2012) F. Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Caspase-8 and Bid: Caught in the act between death receptors and mitochondria
- (2011) Chahrazade Kantari et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells
- (2011) Nicholas S. Wilson et al. CANCER CELL
- A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
- (2011) A. Bertotti et al. Cancer Discovery
- Multivalent DR5 Peptides Activate the TRAIL Death Pathway and Exert Tumoricidal Activity
- (2010) V. Pavet et al. CANCER RESEARCH
- Death Receptor Agonists as a Targeted Therapy for Cancer
- (2010) J. Wiezorek et al. CLINICAL CANCER RESEARCH
- A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
- (2010) R. S. Herbst et al. CLINICAL CANCER RESEARCH
- Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation
- (2010) Annie Yang et al. CURRENT OPINION IN CELL BIOLOGY
- Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
- (2010) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- New insights into apoptosis signaling by Apo2L/TRAIL
- (2010) F Gonzalvez et al. ONCOGENE
- Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5
- (2008) C Adams et al. CELL DEATH AND DIFFERENTIATION
- Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL)
- (2008) Avi Ashkenazi et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started